Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL.

Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.

2.

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.

Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL.

Cancer Res. 2013 Oct 15;73(20):6346-58. doi: 10.1158/0008-5472.CAN-13-1385. Epub 2013 Aug 21.

3.

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.

Rottenberg S, Jonkers J.

Breast Cancer Res. 2012 Nov 5;14(6):324. doi: 10.1186/bcr3327.

4.

Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.

Liu Y, Du F, Chen W, Yao M, Lv K, Fu P.

Exp Cell Res. 2013 Dec 10;319(20):3140-9. doi: 10.1016/j.yexcr.2013.08.023. Epub 2013 Sep 3.

PMID:
24012960
5.

Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.

Gröschl B, Bettstetter M, Giedl C, Woenckhaus M, Edmonston T, Hofstädter F, Dietmaier W.

Int J Cancer. 2013 Apr 1;132(7):1537-46. doi: 10.1002/ijc.27834. Epub 2012 Nov 23.

6.

Redox activation of DUSP4 by N-acetylcysteine protects endothelial cells from Cd²⁺-induced apoptosis.

Barajas-Espinosa A, Basye A, Jesse E, Yan H, Quan D, Chen CA.

Free Radic Biol Med. 2014 Sep;74:188-199. doi: 10.1016/j.freeradbiomed.2014.06.016. Epub 2014 Jun 26.

7.
8.

Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer.

Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Okugawa Y, Shimura T, Hiro J, Uchida K, Mohri Y, Kusunoki M.

Med Oncol. 2013;30(3):620. doi: 10.1007/s12032-013-0620-x. Epub 2013 Jun 8.

PMID:
23749251
9.

DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma.

Schmid CA, Robinson MD, Scheifinger NA, Müller S, Cogliatti S, Tzankov A, Müller A.

J Exp Med. 2015 May 4;212(5):775-92. doi: 10.1084/jem.20141957. Epub 2015 Apr 6.

10.

Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.

Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, Page BD, Gunning PT, Ferri LE, Hallett M, Park M.

Sci Signal. 2014 Apr 22;7(322):ra38. doi: 10.1126/scisignal.2004839.

PMID:
24757178
11.

Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.

Britson JS, Barton F, Balko JM, Black EP.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):849-54. doi: 10.1016/j.bbrc.2009.10.061. Epub 2009 Oct 20.

PMID:
19836351
12.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

13.

Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.

Manzano RG, Martinez-Navarro EM, Forteza J, Brugarolas A.

Int J Oncol. 2014 Dec;45(6):2250-66. doi: 10.3892/ijo.2014.2648. Epub 2014 Sep 9.

14.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL.

Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19.

15.

Regulation of angiopoietin-1/Tie-2 receptor signaling in endothelial cells by dual-specificity phosphatases 1, 4, and 5.

Echavarria R, Hussain SN.

J Am Heart Assoc. 2013 Dec 5;2(6):e000571. doi: 10.1161/JAHA.113.000571.

16.

Tumor necrosis factor-α-mediated suppression of dual-specificity phosphatase 4: crosstalk between NFκB and MAPK regulates endothelial cell survival.

Kao DD, Oldebeken SR, Rai A, Lubos E, Leopold JA, Loscalzo J, Handy DE.

Mol Cell Biochem. 2013 Oct;382(1-2):153-62. doi: 10.1007/s11010-013-1730-7. Epub 2013 Jun 28.

17.

Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.

Li KC, Hua KT, Lin YS, Su CY, Ko JY, Hsiao M, Kuo ML, Tan CT.

Mol Cancer. 2014 Jul 15;13:172. doi: 10.1186/1476-4598-13-172.

18.

Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.

Baglia ML, Cai Q, Zheng Y, Wu J, Su Y, Ye F, Bao PP, Cai H, Zhao Z, Balko J, Zheng W, Lu W, Shu XO.

Breast Cancer Res Treat. 2014 Nov;148(1):211-20. doi: 10.1007/s10549-014-3127-z. Epub 2014 Oct 4.

19.

Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.

Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, Budd GT, Stark GR, Eng C.

Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.

20.

Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.

Nomura M, Shiiba K, Katagiri C, Kasugai I, Masuda K, Sato I, Sato M, Kakugawa Y, Nomura E, Hayashi K, Nakamura Y, Nagata T, Otsuka T, Katakura R, Yamashita Y, Sato M, Tanuma N, Shima H.

Oncol Rep. 2012 Sep;28(3):931-6. doi: 10.3892/or.2012.1862. Epub 2012 Jun 12.

PMID:
22711061

Supplemental Content

Support Center